Boston Scientific (NYSE:BSX) Shares Acquired Sen. John Boozman

Senator John Boozman (R-Arkansas) recently bought shares of Boston Scientific Co. (NYSE:BSX). In a filing disclosed on March 06th, the Senator disclosed that they had bought between $1,001 and $15,000 in Boston Scientific stock on February 13th.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Sprott Lithium Miners ETF (NASDAQ:LITP) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Invesco Short Term Treasury ETF (NYSEARCA:TBLL) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of First Trust North American Energy Infrastructure Fund (NYSEARCA:EMLP) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Motorola Solutions (NYSE:MSI) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Ecolab (NYSE:ECL) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of American Express (NYSE:AXP) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of iShares S&P 500 Growth ETF (NYSEARCA:IVW) on 2/26/2025.

Boston Scientific Stock Performance

Shares of BSX stock opened at $99.15 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm has a market capitalization of $146.33 billion, a price-to-earnings ratio of 79.32, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a one year low of $65.52 and a one year high of $107.17. The company has a 50 day moving average price of $100.45 and a 200 day moving average price of $91.10.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Sell-side analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current year.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors have recently added to or reduced their stakes in BSX. TFC Financial Management Inc. grew its holdings in Boston Scientific by 308.8% during the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 210 shares during the period. Colonial Trust Co SC increased its holdings in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 260 shares in the last quarter. Investment Management Corp VA ADV acquired a new position in shares of Boston Scientific in the 4th quarter worth $25,000. Sunbeam Capital Management LLC acquired a new stake in Boston Scientific during the 4th quarter worth about $26,000. Finally, Dunhill Financial LLC boosted its holdings in shares of Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 152 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares in the company, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the transaction, the executive vice president now owns 28,454 shares in the company, valued at $2,966,329.50. This represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 137,322 shares of company stock worth $14,321,068 over the last 90 days. 0.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

BSX has been the topic of several research reports. JPMorgan Chase & Co. raised their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Monday, December 16th. TD Cowen increased their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, December 12th. StockNews.com downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday. Raymond James raised their price objective on Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a research note on Thursday, February 6th. Finally, Canaccord Genuity Group boosted their target price on shares of Boston Scientific from $98.00 to $101.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Two research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $108.91.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.